Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 88 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Retifanlimab Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma MOST POPULAR ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 FDA Warns That Robotic Surgery May Lower Life Expectancy for Breast... March 1, 2019 The link between Down syndrome and childhood leukaemia September 1, 2022 Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node... August 31, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe For Esophageal Cancer, Immunotherapy Likely to Play Larger Role FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma
